Regeneron Pharmaceuticals REGN Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's pre-tax income?
- Regeneron Pharmaceuticals (REGN) reported pre-tax income of $831.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's pre-tax income changed year-over-year?
- Regeneron Pharmaceuticals's pre-tax income decreased by 8.2% year-over-year, from $905M to $831.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's pre-tax income has grown at a -13.5% compound annual growth rate (CAGR), from $9.33B to $5.23B.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.